CAGRISEMA (Cagrilintide + Semaglutide) Blend – Premium Research Grade
CAGRISEMA represents an advanced dual-pathway metabolic research compound, meticulously formulated by combining Semaglutide (a potent GLP-1 receptor agonist) with Cagrilintide (a long-acting amylin analogue). This unique peptide blend offers researchers an opportunity to investigate synergistic signaling mechanisms crucial for appetite regulation, gastric emptying, satiety, and overall metabolic homeostasis.
As a dedicated B2B supplier, Peptides Skin provides high-purity lyophilized blends specifically designed for controlled in-vitro research. We ensure reproducible scientific results with verified ≥99% purity, supporting the integrity of your studies.
Key Features for Advanced Metabolic Research
- Dual Mechanism of Action: Combines GLP-1 receptor activation (Semaglutide) with amylin receptor agonism (Cagrilintide) for comprehensive metabolic pathway investigation.
- Exceptional Purity: Guaranteed ≥99% purity, rigorously confirmed via High-Performance Liquid Chromatography (HPLC).
- Optimized Stability: Supplied in a lyophilized (freeze-dried) form to ensure extended shelf life and maintain molecular integrity.
- Controlled Manufacturing: Produced under stringent conditions using Solid-Phase Peptide Synthesis (SPPS), ensuring research-grade quality.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | CagriSema (Cagrilintide + Semaglutide) |
| Components | Semaglutide + Cagrilintide |
| Form | Lyophilized White Powder |
| Purity | ≥99% (HPLC Verified) |
| Solubility | Bacteriostatic Water, Sterile Buffers |
| Storage | −20 °C (powder), 4 °C (reconstituted solution) |
Mechanism of Action: Synergistic GLP-1 + Amylin Targeting
Semaglutide functions by mimicking endogenous GLP-1, thereby supporting insulin secretion, modulating appetite, and influencing glucose metabolism. Concurrently, Cagrilintide acts as an amylin receptor agonist, playing a critical role in regulating gastric emptying and significantly enhancing satiety signals.
Research models consistently indicate that the co-administration of these two agents can elicit a synergistic response, often surpassing the individual metabolic effects observed when either compound is used as a monotherapy. This dual agonism provides a more holistic approach to studying complex metabolic pathways.
Research Applications
CAGRISEMA is an invaluable tool for a wide array of advanced research applications:
- Obesity & Metabolic Syndrome Research: Ideal for studying dual-pathway mechanisms involved in adipose tissue reduction and weight management.
- Glycemic Regulation Models: Investigating the synergistic effects of GLP-1 and amylin on glucose homeostasis and insulin sensitivity.
- Cardiometabolic Health Studies: Assessing metabolic markers and their response under combined GLP-1 and amylin agonism.
- Comparative Peptide Research: Facilitates evaluation against other prominent metabolic peptides such as Semaglutide, Tirzepatide, and Retatrutide.
Storage & Handling Guidelines
To ensure the integrity and stability of CAGRISEMA for your research:
- Lyophilized Powder: Store at −20 °C, protected from direct light. Stable for up to 24 months under these conditions.
- Reconstituted Solution: Store at 4 °C and use within 14–21 days. Do not refreeze reconstituted solutions.
- Handling Precautions: Always utilize sterile technique and appropriate Personal Protective Equipment (PPE) during preparation and handling to prevent contamination and ensure safety.
Safety & Disclaimers
RESEARCH USE ONLY — STRICTLY NOT FOR HUMAN OR CLINICAL USE.
CAGRISEMA is provided solely as a research chemical and is not classified as a pharmaceutical product. It must not be used for therapeutic, dietary, cosmetic, or diagnostic purposes in humans or animals. All information and statements herein refer exclusively to laboratory observations and findings in non-human research models.
Why Researchers Trust Peptides Skin for CAGRISEMA
- Verified Purity & Quality: Every batch is accompanied by a Certificate of Analysis (COA), with purity further validated through independent third-party HPLC/MS testing.
- Reliable B2B Supply: Consistent stock availability and meticulously controlled production batches support uninterrupted research timelines.
- Secure & Stable Shipping: Products are shipped using temperature-protected packaging to help maintain molecular stability from our lab to your facility.
Frequently Asked Questions (FAQ)
Is CagriSema more effective than Semaglutide alone in research models?
Research models indicate that combining Cagrilintide with Semaglutide may produce greater effects on weight and metabolic signaling compared to GLP-1 agonism alone. The specific degree of effectiveness observed will depend on the pathways and experimental parameters under investigation.
How do Semaglutide and Cagrilintide differ in their mechanisms?
Semaglutide primarily targets and activates GLP-1 receptors, influencing insulin secretion and appetite. Cagrilintide acts as an agonist for amylin receptors, regulating gastric emptying and enhancing satiety. Together, they modulate appetite, satiety, and gastric emptying through distinct yet complementary biological pathways.
Is the CagriSema blend supplied ready to use?
No. CAGRISEMA is supplied as a lyophilized (freeze-dried) powder. Reconstitution with an appropriate solvent, such as bacteriostatic water or a sterile buffer, is required prior to use in laboratory experiments.
Is CagriSema available for personal or clinical use?
No. This blend is strictly designated for in-vitro laboratory research purposes only and is not intended for human consumption, clinical trials, or any personal therapeutic applications.